Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source
Serious adverse events following human papillomavirus vaccination: A systematic review and meta-analysis of post-marketing evidence. [PDF]
Brown H, Nasreen S.
europepmc +1 more source
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source
Safety profile of progesterone: Insights from an FDA Adverse Event Reporting System (FAERS)-based pharmacovigilance study. [PDF]
Xu R +6 more
europepmc +1 more source
Girls just wanna have funds: a new Transparent Reporting Scale for evaluating grant data reporting from funding agencies. [PDF]
Clarke N +9 more
europepmc +1 more source
Assessing safety trends of withdrawn medications: A data-driven pharmacovigilance approach using growth models. [PDF]
Ghubade S, Shukla S.
europepmc +1 more source
Examining disparities in harmful reporting on community firearm violence in Philadelphia television news reports. [PDF]
Beard JH +9 more
europepmc +1 more source
A Framework to Decipher and Report Implementation Strategies and Pragmatic Attributes of Trial Design Domains From Pre-Implementation Studies Identified From a Systematic Review: A Methodological Study. [PDF]
Ajja R +8 more
europepmc +1 more source

